文献速递神经肿瘤

胶质母细胞瘤中MGMT表达与启动子甲基化的昼夜节律调控构成TMZ敏感性的每日节律基础

Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma.
PubMed 文献 · J Neurooncol · 2024-01-26

该研究在鼠和人胶质母细胞瘤(GBM)模型中验证TMZ疗效依赖给药时间与MGMT活性;体外显示GBM细胞核心时钟基因Bmal1、Per2及MGMT表达存在内源性昼夜节律,Bmal1转录峰值时对TMZ更敏感;小鼠体内早晨给TMZ较晚间缩小肿瘤并增加体重;作者结论为在肿瘤Bmal1表达每日最高、MGMT活性最低时给药可大幅增强TMZ化疗,且评估MGMT甲基化状态需控制活检时间。

要点

  • GBM细胞Bmal1、Per2及MGMT表达存在内源性昼夜节律。
  • Bmal1转录每日峰值时GBM细胞对TMZ更敏感。
  • 小鼠GBM异种移植中早晨给TMZ较晚间缩小肿瘤并增加体重。

核心结论

  • 作者结论为在肿瘤Bmal1表达每日最高且MGMT活性最低时给予TMZ可大幅增强化疗效果,并认为评估MGMT甲基化状态需控制活检时间。

研究设计与样本

  • 研究在鼠和人GBM模型的体外与体内实验中验证TMZ疗效依赖给药时间与MGMT活性的假说。

主要发现

  • 体外实时生物发光报告显示GBM细胞核心时钟基因Bmal1和Per2及DNA修复酶MGMT表达存在内源性昼夜节律。
  • 独立检测MGMT转录本水平与启动子甲基化也显示GBM细胞固有的每日节律。
  • GBM细胞在Bmal1转录每日峰值时对TMZ更敏感。
  • 小鼠GBM异种移植中早晨给予TMZ较晚间给药缩小肿瘤并增加体重。
  • O6-苄基鸟嘌呤抑制MGMT活性后,通过提高Bmal1表达峰值与谷值时的敏感性,消除了体外对TMZ敏感性的每日节律。

临床怎么用

  • 作者认为在肿瘤Bmal1表达每日最高且MGMT活性最低时给予TMZ可大幅增强化疗效果。
  • 作者认为评估MGMT甲基化状态需控制活检时间。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) is the most common primary brain tumor in adults. Despite extensive research and clinical trials, median survival post-treatment remains at 15 months. Thus, all opportunities to optimize current treatments and improve patient outcomes should be considered. A recent retrospective clinical study found that taking TMZ in the morning compared to the evening was associated with a 6-month increase in median survival in patients with MGMT-methylated GBM. Here, we hypothesized that TMZ efficacy depends on time-of-day and O6-Methylguanine-DNA Methyltransferase (MGMT) activity in murine and human models of GBM. METHODS AND RESULTS: In vitro recordings using real-time bioluminescence reporters revealed that GBM cells have intrinsic circadian rhythms in the expression of the core circadian clock genes Bmal1 and Per2, as well as in the DNA repair enzyme, MGMT. Independent measures of MGMT transcript levels and promoter methylation also showed daily rhythms intrinsic to GBM cells. These cells were more susceptible to TMZ when delivered at the daily peak of Bmal1 transcription. We found that in vivo morning administration of TMZ also decreased tumor size and increased body weight compared to evening drug delivery in mice bearing GBM xenografts. Finally, inhibition of MGMT activity with O6-Benzylguanine abrogated the daily rhythm in sensitivity to TMZ in vitro by increasing sensitivity at both the peak and trough of Bmal1 expression. CONCLUSION: We conclude that chemotherapy with TMZ can be dramatically enhanced by delivering at the daily maximum of tumor Bmal1 expression and minimum of MGMT activity and that scoring MGMT methylation status requires controlling for time of day of biopsy.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Gonzalez-Aponte MF, Damato AR, Trebucq LL, et al. Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma. J Neurooncol. 2024. PMID: 38277015. doi:10.1007/s11060-023-04535-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。